Patients who relapse early after first-line chemotherapy are often, but not always, refractory to second-line chemotherapy
Elevated levels of vWF and FVIII associated with risk of blood clots, severe COVID-19 and death
Study matches momelotinib against danazol
Key abstracts highlight advances in treating locally advanced and refractory disease
Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy
Majority of patients achieve complete pathologic response after four-dose cemiplimab therapy
New BMT leadership looks to clinical research and cell therapy production to overcome treatment access limitations
Pilot Study at Cleveland Clinic is Testing Feasibility and Biodistribution
Breaking through barriers in cancer care
Pathogenic POLE/POLD1 mutations lead to improved response to immune checkpoint blockade therapy
Blinatumomab followed by POMP maintenance shows effectiveness for newly diagnosed patients